DeSci Project NanoVita Completes Strategic Funding Round with Paramita and Others

iconChaincatcher
Share
Share IconShare IconShare IconShare IconShare IconShare IconCopy
AI summary iconSummary

expand icon
The DeSci project NanoVita has announced the completion of a strategic funding round, with participants including Paramita, Harbor Digital Ventures, and Apus Capital. The funding amount has not been disclosed. NanoVita integrates nanotechnology, AI bio-intelligence, and real-world health data to build an open health research infrastructure. Previously, the project secured seed funding from CGV, UDS Space, and Candaq Fintech Group, along with Pre-A support from K24 Ventures and LandScape Capital. This funding announcement follows a series of key investment milestones.

ChainCatcher report: The DeSci project NanoVita has officially announced the completion of a strategic funding round, with the amount undisclosed. This round was led by Paramita, Harbor Digital Ventures, and Apus Capital. NanoVita is a decentralized science (DeSci) protocol that integrates nanotechnology, AI-driven biological intelligence, and real-world health data to build an open and transparent infrastructure for health research. Additionally, NanoVita previously completed a seed round led by Cryptogram Venture (CGV), UDS Space, Candaq Fintech Group, and Susie Venture, as well as a Pre-A round led by K24 Ventures, LandScape Capital, and WestLabs.

Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information. Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.